Aspect Partners’s Moderna MRNA Stock Holding History

Aspect Partners’s Portfolio MRNA Stock Details MRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$1.16K	Buy	+6	New	+$647	﹤0.01%	567

Other funds holding MRNA

Banque Pictet & Cie Geneva 73, Switzerland $14.5B AUM 33.71% 1-Year Est. Return

Douglas Lane & Associates New York $7.46B AUM 24.36% 1-Year Est. Return

Beau Ventures, LLc Pittsford, New York $1.06B AUM 83.06% 1-Year Est. Return

New York State Teachers Retirement System (NYSTRS) Albany, New York $52.9B AUM 36.03% 1-Year Est. Return

FNY Investment Advisers New York $402M AUM 85.9% 1-Year Est. Return

Czech National Bank Prague, Czech Republic $18.9B AUM 36.24% 1-Year Est. Return

TD Waterhouse Canada Toronto, Ontario, Canada $38.4B AUM 30.28% 1-Year Est. Return

LAI

Legal Advantage Investments Los Altos Hills, California $468M AUM 7.83% 1-Year Est. Return

Y-Intercept (HK) Hong Kong $4.52B AUM 6.6% 1-Year Est. Return

BI Asset Management Fondsmaeglerselskab Kobenhavn, Denmark $13.1B AUM 35.37% 1-Year Est. Return

Aspect Partners's MRNA Position: Q3 2026 in Review

Aspect Partners opened a new position in Moderna (MRNA) in Q3 2026: 6 shares worth $1.16K. The stake represents ﹤0.01% of the portfolio and ranks #567 among its holdings.

195 funds tracked by Wall St. Rank hold MRNA as of Q3 2026.

Aspect Partners held 6 shares of Moderna worth $1.16K as of Q3 2026.
Moderna was a new Aspect Partners position in Q3 2026.
Moderna made up ﹤0.01% of Aspect Partners's portfolio in Q3 2026, its #567 holding.
195 funds tracked by Wall St. Rank held Moderna as of Q3 2026.

Based on Aspect Partners's 13F filing for Q3 2026, filed 20 Oct 2026.